Determining the genetic basis of cancer requires comprehensive analyses of large collections
of histopathologically well-classified primary tumours. Here we report the results of a …

Massively parallel DNA sequencing technologies provide an unprecedented ability to
screen entire genomes for genetic changes associated with tumour progression. Here we …

The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in
glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular …

Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse,
which is associated with clonal evolution at the cytogenetic level 1 , 2 . To determine the …

Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about
13,000 adults in the United States each year. The treatment of this disease has changed little in …

Early T-cell precursor acute lymphoblastic leukaemia (ETP ALL) is an aggressive malignancy
of unknown genetic basis. We performed whole-genome sequencing of 12 ETP ALL cases …

Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co-…

Cancer is a disease driven by genetic variation and mutation. Exome sequencing can be
utilized for discovering these variants and mutations across hundreds of tumors. Here we …

The Cancer Genome Atlas (TCGA) has used the latest sequencing and analysis methods to
identify somatic variants across thousands of tumours. Here we present data and analytical …

Background Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is
characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL, …